TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9778008
Drug: Superficial cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial cervical plexus block with 20 ml bupivacaine, 0.375%
Study: 8164824
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone per day
Study: 8164824
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone per day
Study: 8164824
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg dexamethasone per day
Study: 3408828
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 80 mg methylprednisolone in 10 ml physiological saline
Study: 3408828
Drug: Interspinous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interspinous injection of 2 ml physiological saline
Study: 31353217
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment (IPT) with dihydroartemisinin-piperaquine (4 and 18 mg/kg per day)
Study: 31353217
Drug: Intermittent Screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Screening and Treatment (IST) with monthly malaria rapid diagnostic tests
Study: 31353217
Drug: Single Screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Screening and Treatment (SST)
Study: 24266552
Drug: Active analgesic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active analgesic strategy with pre-medication with oral midazolam mixture and intravenous alfentanil and midazolam regularly administered during the procedure
Study: 24266552
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with morphine and diazepam (control group)
Study: 15488867
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in triglycerides (n=19, median: -18 mg/dl)
Study: 15488867
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in triglycerides (n=20, median: +44 mg/dl)
Study: 11125269
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone solution
Study: 27871603
Drug: Prophylactic infusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusion of phenylephrine (100-μg/mL solution at 1 mL/min)
Study: 27871603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.9% isotonic sodium chloride solution)
Study: 24150200
Drug: Ca+MZn+D group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca+MZn+D group (zinc, 15 mg/day + multivitamins; calcium, 500 mg/day; vitamin D, 30,000 IU/3 months)
Study: 24150200
Drug: Ca+D group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca+D group (calcium, 500 mg/day; vitamin D, 30,000 IU/3 months)
Study: 22486143
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg i.v. and Ketamine 0.5 mg/kg i.v. (Group KD)
Study: 22486143
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg i.v. (Group D)
Study: 22486143
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg i.v. (Group K)
Study: 20649409
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (6 biannual mass distributions)
Study: 19011472
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) therapy (30 mg/kg/d for 3 d then 20 mg/kg/d for 4 d)
Study: 19011472
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) therapy
Study: 15738450
Drug: Special intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special intervention group (nutrition counseling, smoking cessation, increased physical activity, intensive blood pressure treatment)
Study: 3786346
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg nicotine gum)
Study: 23837461
Drug: Zonisamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (1 mg/kg/day titrated to 8 mg/kg/day over 8 weeks, maintained for 12 weeks)
Study: 17488363
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg twice daily for 6 weeks
Study: 11354518
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of temazepam
Study: 9059318
Drug: Mechanical oesophageal
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical oesophageal stimulation (0.5 s, 14 ml, 0.2 Hz)
Study: 23435159
Drug: Basal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal plus regimen with glargine once daily and supplemental doses of glulisine
Study: 19123335
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and nursing (Control)
Study: 16095766
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of SsWC on Days 0, 14, and 28 (N = 3)
Study: 16095766
Drug: Five doses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five doses of SsWC on Days 0, 2, 4, 6, and 28 (N = 4)
Study: 16095766
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens of SsWC
Study: 12912816
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg single dose)
Study: 12912816
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg BID for 6 months)
Study: 12912816
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg extended-release daily for 6 months)
Study: 10792115
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg o.d.)
Study: 8852907
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine (OPV)
Study: 2060435
Drug: d-fenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (15 mg/day for 1 week)
Study: 27790756
Drug: Adapalene 0.1%/benzoyl
Normalized name: ADAPALENE 0.1%/BENZOYL PEROXIDE 2.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1%/benzoyl peroxide 2.5% gel (A/BPO)
Study: 17385938
Drug: Drospirenone in
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone in combination with estrogen
Study: 17385938
Drug: Oral progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral progestogen preparations (control)
Study: 15735107
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple micronutrient (DMM) supplement
Study: 15735107
Drug: Weekly multiple
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multiple micronutrient (WMM) supplement
Study: 15735107
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron (DI) supplements
Study: 8846749
Drug: L-propionyl carnitine
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionyl carnitine (2 g by slow infusion b.i.d, plus heparin and buflomedil)
Study: 8846749
Drug: Placebo (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plus heparin and buflomedil)
Study: 2361811
Drug: Long duration
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long duration exercise (L‐EX)
Study: 389824
Drug: Bacampicillin 400
Normalized name: bacampicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 400 mg plus 1 g probenecid
Study: 389824
Drug: Bacampicillin 800
Normalized name: bacampicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 800 mg plus 1 g probenecid
Study: 389824
Drug: Bacampicillin 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 1600 mg plus 1 g probenecid
Study: 26187147
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (10Hz for 3 weeks)
Study: 12630982
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (n = 54)
Study: 10715931
Drug: Power toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Power toothbrush (Braun Oral‐B Ultra Plaque Remover, Braun GmbH)
Study: 1529284
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (10 g/day)
Study: 2868467
Drug: Prophylactic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic maintenance medication
Study: 29394018
Drug: C‐T (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐T (cream applied with repeated toner every 2 h)
Study: 29394018
Drug: C+T (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+T (cream and toner applied successively)
Study: 29394018
Drug: T+C (toner
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+C (toner and cream applied successively)
Study: 29394018
Drug: C (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (cream only)
Study: 29394018
Drug: C‐S (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐S (cream applied with repeated spray water every 2 h)
Study: 23033520
Drug: HIV antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV antibody test
Study: 18089865
Drug: Gemcitabine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine infusion over 100 minutes
Study: 18089865
Drug: Gemcitabine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine infusion over 30 minutes
Study: 9702852
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of digoxin alone (Phase 1)
Study: 9702852
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of digoxin after 200 mg of acarbose (Phase 2)
Study: 9702852
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of digoxin after 100 mg of acarbose (Phase 3)
Study: 2657105
Drug: Yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride (maximum of 42.0 mg orally daily)
Study: 4938431
Drug: Levodopa (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (maximum tolerated dosage)
Study: 4938431
Drug: Levodopa +
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa + L-alpha-methyldopahydrazine
Study: 29847672
Drug: PF-04634817 200
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04634817 200 mg once-daily (QD) plus placebo
Study: 29847672
Drug: Ranibizumab 0.3/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3/0.5 mg monthly plus oral placebo
Study: 23104718
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care education
Study: 15176768
Drug: Hallucination focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hallucination focused integrative treatment (HIT)
Study: 9806657
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with carboplatin (600 mg/m2 on Day 1), cyclophosphamide (250 mg/m2 on Day 1), and cisplatin (100 mg/m2 on Day 8 every 4 weeks) with or without amifostine (740‐1140 mg/m2)
Study: 9806657
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with carboplatin, cyclophosphamide, and cisplatin
Study: 2679048
Drug: Nifedipine (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10-30 mg before meals)
Study: 18371107
Drug: COPAD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPAD chemotherapy (cyclophosphamide, vincristine, prednisolone, and doxorubicin), given in two courses without intrathecal chemotherapy.
Study: 9822485
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone (6 mg every 12 hours for 4 doses, repeated weekly until 34 weeks' gestation)
Study: 9822485
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (8 mg every 12 hours for 4 doses, repeated weekly until 34 weeks' gestation)
Study: 7858362
Drug: i.v.‐PCA ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.‐PCA ketorolac 5 mg/ml
Study: 7858362
Drug: i.v.‐PCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.‐PCA morphine 1 mg/ml
Study: 30792143
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g PS
Study: 30792143
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g OBG
Study: 30792143
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g PS and 3 g OBG
Study: 28640772
Drug: Carbohydrate mouth
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate mouth rinse (25 ml of an 18% CHO solution)
Study: 17267793
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine
Study: 7648784
Drug: Insulin modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin modified FSIVGTT (insulin infusion at 4 mUkg‐1.min‐1 from time 20 to 25 min)
Study: 7648784
Drug: Standard FSIVGTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FSIVGTT (glucose infusion of 0.3 g/kg from time 0 to 2 min)
Study: 2953752
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate administered daily for 4 weeks followed by concomitant hMG administration
Study: 31251544
Drug: Low-density MFU-V
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density MFU-V treatments
Study: 31251544
Drug: High-density MFU-V
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density MFU-V treatments
Study: 31251544
Drug: High-density MFU-V
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density MFU-V treatment
Study: 27068760
Drug: Anti-malarial treatment
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-malarial treatment (specific dosage and duration not provided)
Study: 24558011
Drug: Hot drink
Normalized name: Nature's Way Cold Relief Hot Drink Lemon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot drink (paracetamol)
Study: 24558011
Drug: Tablet (paracetamol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (paracetamol)
Study: 22721545
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - 1 g loading dose followed by 1 g maintenance dose over 8 hours
Study: 17227744
Drug: Homeopathic combination
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic combination medication
Study: 15943961
Drug: Oxytrex bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytrex bid (twice a day)
Study: 17157780
Drug: Oxycodone qid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone qid
Study: 12213107
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg day(-1))
Study: 7704460
Drug: Slow‐acting anti‐rheumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow‐acting anti‐rheumatic drugs (SAARD)
Study: 2696292
Drug: 3% Felbinac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Felbinac gel (1 or 2 g)
Study: 2696292
Drug: Oral Fenbufen
Normalized name: fenbufen
DrugBank: Fenbufen (DB08981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fenbufen (300 mg thrice daily)
Study: 2696292
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration (Felbinac gel)
Study: 2696292
Drug: Skin tissue
Normalized name: skin tissue adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin tissue concentrations after topical administration
Study: 773080
Drug: Madopar (L-Dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar (L-Dopa + benserazid)
Study: 28120127
Drug: ONO-8539 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-8539 (450 mg)
Study: 25644589
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment during follow-up
Study: 24702710
Drug: AS03-adjuvanted inactivated
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted inactivated trivalent split-virion influenza vaccine (AS03-TIV)
Study: 24702710
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (TIV)
Study: 22348696
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 1.2-mg SMV
Study: 18069280
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (SCT)
Study: 18069280
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs including thalidomide, lenalidomide, or bortezomib in combination with SCT
Study: 9308335
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for epilepsy
Study: 6870066
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy (hydralazine or nifedipine) for Group I; nitroprusside followed by minoxidil or hydralazine for Group II.
Study: 28389025
Drug: 4-implant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-implant group
Study: 21029429
Drug: Ibuprofen, 600
Normalized name: Ibuprofen, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 600 mg thrice daily
Study: 15813357
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after the first seizure
Study: 15813357
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam at seizure onset
Study: 1916649
Drug: met‐hGH (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: met‐hGH (0.08 mg/kg desirable body weight)
Study: 25228126
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of prednisone daily for 2 years
Study: 23230115
Drug: High nitrogen
Normalized name: Isosource High Nitrogen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrogen (HN; CON plus urea supplement)
Study: 19913145
Drug: ETG-releasing implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETG-releasing implant
Study: 16762627
Drug: Entecavir 1
Normalized name: entecavir 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1 mg daily
Study: 7956657
Drug: ThinPrep preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThinPrep preparation
Study: 3604619
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU heparin and 0.5 mg dihydroergotamine injected subcutaneously twice daily
Study: 27545858
Drug: NTP‐CE (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTP‐CE (new topical panthenol‐containing emollient)
Study: 19353407
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive treatment (indapamide 1.5 mg sustained release +/‐2‐4 mg perindopril)
Study: 12717213
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg per dose every 14 days for five doses (group I, n=107)
Study: 12717213
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg per dose every 14 days for two doses (group II, n=112)
Study: 12717213
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction (group III, n=78)
Study: 12717213
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg per dose every 14 days for five doses (group I)
Study: 12717213
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg per dose every 14 days for two doses (group II)
Study: 12717213
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction (group III)
Study: 24286472
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of adalimumab (ADA)
Study: 19186727
Drug: Acupoint stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint stimulating therapy
Study: 15086180
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during colonoscopy, n=15
Study: 9731580
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA level > 100 x 10(5) Eq/mL at 1 month after transplantation
Study: 2807006
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus twice-weekly cis-platinum (group III)
Study: 2807006
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus weekly cis-platinum (group II)